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The Grb-2 associated binder (Gab) family of scaﬀolding/adaptor/docking proteins is a group of three molecules with signiﬁcant
roles in cytokine receptor signaling. Gabs possess structural motifs for phosphorylation-dependent receptor recruitment, Grb2
binding, and activation of downstream signaling pathways through p85 and SHP-2. In addition, Gabs participate in hematopoiesis
and regulation of immune response which can be aberrantly activated in cancer and inﬂammation. The multifunctionality of
Gab adapters might suggest that they would be too diﬃcult to consider as candidates for “targeted” therapy. However, the one
drug/one target approach is giving way to the concept of one drug/multiple target approach since few cancers are addicted to a
single signaling molecule for survival and combination drug therapies can be problematic. In this paper, we cover recent ﬁndings
onGabmulti-functionality,bindingpartners,andtheirroleinhematologicalmalignancyandexaminetheconceptofGab-targeted
therapy.
1. Discovery and Similarities of
GabFamilyMembers
The Gab proteins, Gab1, Gab2, and Gab3, comprise a
family of scaﬀolding/docking molecules involved in multiple
signaling pathways mediated by receptor tyrosine kinases
(RTKs) and non-RTK receptors. Gab proteins integrate and
amplify signals from a wide variety of sources including
growth factor, cytokine, and antigen receptors, as well as cell
adhesion molecules. They are subject to complex regulation
by feedforward and feedback phosphorylation events as well
as protein-protein interactions. Gab proteins range from
50 to 100kDa in size [1] and were originally identiﬁed
as the mammalian homologs of the daughter of sevenless
(DOS) Drosophila adapter proteins [2, 3]. They also display
sequencesimilaritytoSuppressor of Clear 1(Soc1),whichwas
identiﬁed by genetic screen in C. elegans [3, 4].
Gab1 was originally identiﬁed as a binding protein for
Grb-2 [5], and Gab2 was isolated by the puriﬁcation of a
binding partner for SHP [6]. The discovery of Gab3 was
aided by a large sequencing project, and its isolation was
based on sequence similarities to Gab1 and Gab2 [7]. Very
recent entries at both the genomic DNA and transcript
level have been recorded for Gab4 gene in both humans
a n dc h i m p a n z e e s ,b u tt h i sg e n ei sn o tp r e s e n ti nm i c e .T h e
human Gab4 gene is located on chromosome 22q11.1 and its
nucleotide sequence is most related to Gab2 [8].
The overall sequence homology between Gab family
members is about 40–50%. All Gab proteins share a similar
modular structure, including a Pleckstrin homology (PH)
domain at their N-terminus, proline-rich regions in the
central part, and multiple phosphorylated tyrosine residues
(Figure 1). The PH domain is an approximately 100 amino
acid domain that binds phosphoinositides. Gab2 binds pref-
erentially to the PI-3K product phosphatidylinositol-3,4,5-
trisphosphate (PIP3), which is only found within the plasma
membrane [9]. The PH domain mediates recruitment of
Gab2 to phagocytic cups induced by FcγRI and is required
for ﬁbroblast growth factor-induced tyrosine phosphoryla-
tion of this docking protein. The PH domain might play an
important role to localize or to concentrate Gab proteins to
membrane areas where receptors are activated [2].2 Advances in Hematology
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Figure 1: Gab structure and multiple binding sites. Gab molecules
were originally identiﬁed as the mammalian homologs of the
daughter of sevenless (DOS) drosophila adapter protein. Gab1,
Gab2, and Gab3 share many common binding sites. All three
Gabs have a PH domain in the amino-terminus that is believed to
be essential for many functions including membrane localization.
Gabscontainmultiplebindingsitesandactasscaﬀoldingmolecules
to support cytokine signaling. Binding sites for Grb2, Crk, PI3-K,
and SHP-2 have been deﬁned and extensively studied.
The phosphotyrosine domains and the proline-rich
sequences (PXXP) are potential binding sites for Src homol-
ogy2 (SH2) and SH3 domains, respectively. The positions of
the SH2-binding tyrosine-based motifs and the SH3-binding
proline-rich sequence are conserved among the Gabs. These
are one of the most prominent motifs in signaling molecules
due to their relevance in binding and “docking’’ phosphoryl-
ated tyrosine residues or directing protein-protein interac-
tion [10, 11].
These adapter proteins serve important roles in cytokine
receptor signaling by acting as a scaﬀold and coordinat-
ing interactions between signaling intermediates. Multiple
protein binding motifs are present in many of the adapter
molecules leading to multimeric complexes that may also
include proteins such as CrkL [12], PLC-γ [13], SHIP [14],
SHP-2 [15], STAT3 [16], and STAT5 [17].
2. Involvement in Normal and
Leukemic SignalingPathways
As mentioned above, one of the fundamental mechanisms
for regulation of Gab-mediated signal transduction is site-
speciﬁc tyrosine phosphorylation of these proteins. These
molecules are involved in the phosphatidylinositol-3 kinase
(PI3-K) and mitogen-associated protein kinase (MAPK)
pathways and include multiple protein binding sites [18]. To
further elaborate, Figure 2 illustrates how Gab2 is involved
in PI-3K and MAPK pathways. These proteins are tyro-
sine phosphorylated following cytokine stimulation which
enables interaction with a large number of partners. Table 1
summarizes a few key receptors which are associated with
hematopoiesis, some of which are also found mutated in
association with hematologic malignancy. Serine phospho-
rylation of Gabs by downstream eﬀectors also has been
described [19, 20], which will be discussed later.
The signiﬁcance of the phosphorylation sites present
on Gabs not only lies in aiding its interaction with crucial
binding partners, but also on how it inﬂuences activation
of downstream cytokine receptors. Interaction between
the protein tyrosine phosphatase Shp2 and Gab2 regu-
lates MAPK pathway activation. Notably, mast cells and
macrophages from Gab2−/− mice have decreased Erk acti-
vation in response to SCF [27]. Gab2-Shp2 complex also
appears to have an additional, distinct signaling role in
response to other stimuli. For example, overexpression of
Gab2Y604F/Y633F mutant fails to bind to Shp2 and blocks IL-3-
evoked gene activation [6]. Further, the Gab/Shp2 complex
also positively regulates other downstream pathways. These
include c-Kit-induced Rac activation [28], where Gab2 via
Shp-2 transmitted signals from Kit receptor (Tyr-567) to
activate the Rac/JNK pathway. This in turn is signiﬁcant for
mastcelldevelopment[28].Anotherexampleofdownstream
regulation is the Gab2-mediated PI3K activation wherein,
this activation is necessary for epidermal growth factor-
(EGF-) induced DNA synthesis in rat hepatocytes [58, 59].
It is noteworthy that persistent activation of c-Kit and c-
Mpl induces hematological malignancies. Activation of PI-
3K by c-Kit is dependent both on the direct PI3K-binding
site in c-Kit and on the phosphorylation of Gab2 [54].
The fact that c-Kit has been found mutated in numerous
human malignancies, including acute myeloid leukemia, and
that Gab2 is often overexpressed in acute myeloid leukemia
suggests a potential role of Gab2-mediated PI3K activation
in transformation [60]. TPO-induced stimulation of c-Mpl
has been implicated in maintaining HSC quiescence and also
in myeloproliferative disorders (MPDs) and Gabs play a role
in regulating PI-3K and MAPK pathways, in c-Mpl/TPO
signaling [55, 61].
3. FunctionalRole inHematopoiesis Deﬁned by
Knockout Mice
Given their integral role in cytokine signaling, it was pro-
posed that Gabs may play important roles in hematopoiesis.
However, to date, very little is known about how multiple
Gabs regulate hematopoietic cytokine signaling.
Gab1 deﬁciency results in embryonic lethality due to
developmental defects in heart, placenta, skin, and a reduced
ra t i oo fl i v e rt ob o d yw e i gh ta tE 1 4 . 5[ 62, 63]. Also associated
with these defects was reduced Erk activation in embryonic
ﬁbroblasts in response to stimulation with platelet-derived
growth factor (PDGF), epidermal growth factor (EGF),
and hepatocyte growth factor (HGF). These defects were
initially observed to be similar to mice lacking expression
of MET receptor, HGF, PDGF, and EGF growth factors with
phenotypessuchasopeneyelids[64],abnormalhairfollicles
[65],hemorrhageandcardiachypoplasia[66],andabnormal
placenta [67–69]. Later generation of SHP-2 mutant mice
revealed yet again similar defects [70] indicating an essen-
tial central role for Gab1/SHP-2 interactions in mediating
growth factor activation of the Erk MAP kinase pathway.
More recent conditional deletion of Gab1 led to deﬁcient Erk
signaling which allowed increased insulin receptor substrateAdvances in Hematology 3
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Figure 2: Gab2 interactions with binding partners. Diagram shows generic Gab adapter docked at the plasma membrane by the PH domain.
Interactions with p85 and SHP-2 are involved in Akt and Erk activation respectively. Binding of receptor tyrosine kinases to their receptive
ligands triggers the kinase activity of the cytoplasmic domain of the receptor. The receptor becomes phosphorylated on tyrosine residues.
Docking proteins suchas Grb2 contain SH2 domains that bindtothe phosphotyrosineresidues of theactivated receptor. Grb2-Gabinteracts
through the SH3 domains and activates downstream signaling pathways, PI-3K/Akt and SHP2/Erk. Grb-2 can bind to SOS via N-terminal
SH3 domain while the C-terminal SH3 domains are used for its interaction with Gab proteins. SOS-1 has been known to associate with
Grb2, leading to its autophosphorylation. This complex gets translocated to the activated receptor where it then associates with Ras. As
Ras gets activated it induces the downstream ERK/MAPK pathway. Alternatively, stimuli from growth factors like EGF, VEGF, and so forth,
causes binding of Gab2 to Grb2. This then leads to recruitment of SHP2, that binds to phosphorylated tyrosine residues on Gab, and in turn
activates ERK/MAPK signaling. Negative feedback by serine phosphorylation of Gab at S160 by Akt and S623 by Erk (block arrows) plays an
important role in control of function and signaling of Gabs.
(IRS) activation to enhance glucose tolerance and improve
hepatic insulin action [71]. A role for Gab1 as an adapter
protein linking gp130 signaling to the Erk pathway has also
been described [39]. Gab1−/− c e l l sa r ed e f e c t i v ei nr e s p o n s e
to gp130 activation through IL-6 and the soluble IL-6Rα
[62].
Gab2 is tyrosine phosphorylated at any of 19 sites by
several early-acting cytokine receptors such as Flt3, c-Kit,
IL-3R, and c-Mpl. Gab2 contains SH2 domain binding sites
and 5 PxxP sites (polyProline sites) that bind SH3 domain
[6, 18, 29]. Consistent with binding of p85 and SHP-2, Gab2
activates the PI3-K and the MAPK pathways, respectively,
which may participate in regulating hematopoietic cell
migration functions [48]. Gab2−/− m i c ea r ev i a b l eb u tl a c k
allergic response [72] since Gab2 deﬁciency has also been
shown to alter mast cell development [27] in a manner
similar to STAT5-deﬁcient mice [73]. Use of point-mutants
[36, 48, 74], that deter Gab2 binding to signaling partners,
could help to dissect the structure-function relationship of
Gab2 in vivo. A recent study has established Gab2 ΔSHP2
(Y603F/Y632F) and Gab2 ΔPI3K (Y441F/Y465F/Y573F)
mutant knockin mice [75], with Gab2 mutated at SHP-2
and PI3K binding sites, respectively. Further assessment of
these mice has shown that the PI3K or SHP2 binding sites
in Gab2 are important for mast cell degranulation and the
anaphylaxis response.
Despite the normal appearance, normal BM cellularity,
and normal blood counts of mice lacking Gab2 expression,
Gab2−/− mice show reduced colony forming ability in
methylcellulose and impaired KLS (c-Kit+ Lin− Sca-1+ cell
surface markers denoting mouse hematopoietic stem cell)
cell growth in liquid culture [76]. The defects of these cells
in response to early-acting cytokines like SCF, TPO, and IL-3
suggest that Gab2 may act as an intermediate relay protein
that organizes signaling complexes and ampliﬁes receptor
activation. Owing to these ﬁndings, Gab2 can be a potential
target molecule for better understanding steady-state and
aberrant hematology.4 Advances in Hematology
Table 1: Gabs are associated with multiple common hematopoietic receptors, RTK: receptor tyrosine kinase.
Receptor Ligand Cell type Phosphorylated References
Gab1 Gab2 Gab3
RTK
Flt3 Flt3L BaF3/Flt3, THP-1, RS4; 11 Yes Yes Yes [7, 21]
Fms M-CSF FDFms, 32D-Fms, EML-Fms, BAC1.2F5, 32D,
BMDM
NR Yes Yes [6, 7, 22–26]
Kit SCF FDFms, MO7E, MC9, BMMC Yes Yes NR [23, 27–30]
Non-RTK
EPO receptor EPO BaF3, UT-7, HCD-57, primary erythroid cells,
R1, Namalwa, FDC-P1
Yes Yes NR [13, 31–34]
G-CSF receptor G-CSF BaF3, DT40 NR Yes NR [35]
GM-CSF receptor GM-CSF FDFms, BaF3, UT-7 Yes Yes NR [23, 36–38]
gp130 IL-6, LIF HepG2, BAF-B03, T47D, MM.1S, cardiomyo-
cytes
Yes Yes NR [29, 39–43]
IL-15 receptor IL-15 T cells, MyLa2059 NR Yes NR [44, 45]
IL-2 receptor IL-2 Kit225, KT-3, T-cell blasts, T cells, NK3.3,
MyLa2059
NR Yes NR [18, 19, 29, 45–47]
IL-3 receptor IL-3 BaF3, BAF-B03, primary hematopoietic cells,
NIH 3T3
Yes Yes Yes [29, 48–53]
Mpl TPO TF-1, UT-7, BaF3, primary megakaryocyte pro-
genitors
Yes Yes NR [54–57]
NR: not reported.
In contrast to Gab1 and Gab2 which have ubiquitous
expression in brain, kidney, lung, heart, and ovary [5, 6,
9], Gab3 is localized to hematopoietic tissues [7, 77]. An
additional diﬀerence between Gab3 and Gab1/2 is that it
may not be able to interact with Crk or Crkl but has unique
potential binding sites that have yet to be characterized [7].
Gab3 SH3 domains have been shown to associate with a
number of Src family kinases including Src, Fyn, and Lyn
[7]. Increased Gab3 expression is observed following M-
CSF stimulation of myeloid and macrophage cell lines [7],
and diﬀerentiation is facilitated by overexpression. However,
Gab3 knockout mice do not have obvious hematopoietic
phenotypes [78] and have normal macrophage numbers.
4. Supporting Role for Gabs in
Cancer Progression
It is well established that Gab proteins promote tumor-
genesis by functioning as “accomplices” of certain oncopro-
teins or by amplifying signaling upon their overexpression.
This type of “nononcogene addiction” has been described
for molecules that become essential in the setting of cancer,
but they are not mutated or capable of transformation
on their own. In addition to normal cytokine activation,
Gab1 and Gab2 can also be activated by oncogenic tyrosine
kinases, oncoproteins, and Src family kinases (summarized
in Table 2). Gab3 has not yet been described to play a role in
cancer signaling.
The study of Gab1 in Met signaling and cancer has
been researched in recent years. Overexpression of Gab1
promotes cell cycle progression when Met is expressed at
Table 2:Gab1andGab2areactivatedbykinases,oncoproteins,and
other adaptors in cancer cells.
Cancer Gab activator Gab1 Gab2
Breast [79–83] Ampliﬁcation,
ErbB2, Src Yes Yes
Glioblastoma [84]M e t Y e s N o
Thyroid [85]R e t Y e s N o
Gastric [86] Ampliﬁcation No Yes
Myeloma [40]H c k Y e s Y e s
Chronic myelogenous leukemia
[53, 87] Bcr/Abl No Yes
Friend virus erythroblastosis
[16, 88] Sf-Stk No Yes
Anaplastic large cell lymphoma [89]N P M - A l k N o Y e s
Acute myeloid leukemia [90, 91] Flt3-ITD ? Yes
Myeloproliferative disease [92] JAK2V617F ?Y e s
suboptimal levels. For this response, it is required for Gab1
to possess an intact Met-binding motif, the PH domain, and
the binding sites for PI3-K and SHP-2. In this model, Gab1
suﬃciently promoted transformation and proliferation of
ﬁbroblasts [93]. A role for Gab1/Shp-2 interaction in growth
and transformation of NIH 3T3 ﬁbroblasts has also been
reported [94], although this has not yet been validated in
vivo for disease induction. It was shown in recent studies
that Gab1 expression increased cell motility and adhesion
of myeloid 32D cells in a hepatocyte growth factor (HGF)
stimulated setting. In this setting, Gab1 was also seen to upAdvances in Hematology 5
regulate GATA-2, which has been implicated in CML and
could be a key player in malignant transformation [95].
Involvement of Gab2 in leukemogenesis was highlighted
when myeloid progenitors from Gab2-deﬁcient mice were
found to be resistant to transformation by Bcr-Abl [87].
Phosphorylation of Y177 within the Bcr moiety leads to
recruitment of the Grb2/Gab2 complex and triggers down-
stream signaling via SHP2 and PI-3K, which is crucial for
enhancedproliferation andsurvival.Similarly, the oncogenic
Bcr-FGFR1 fusion protein, which is also the product of a
chromosomal translocation, drives the tyrosine phospho-
rylation of Gab2 in murine bone marrow cells and their
malignant transformation through phospho-Y177 mediated
Grb2 association [96]. Another kinase implicated as a key
component of the Bcr-Abl signaling network is Jak2 that
in turn activates Lyn leading to Gab2 phosphorylation.
These ﬁndings highlight the role of Gab2 phosphorylation
in driving chronic myeloid leukemia (CML) [97]. After the
pivotal role of Gab2 in Bcr-Abl-mediated transformation
had been established, its involvement in the pathogenesis
of several other leukemias was discovered. The oncogenic
fusion kinases Tel-Abl and Tel-Jak2 engage Gab2 in a
similar manner to Bcr-Abl [98, 99]. Likewise, it was seen
that introduction of a germline gain-of-function SHP2
mutation, D61G/+, induced MPD by aberrant activation
of HSCs and the disease phenotype was improved in the
Ptpn11(D61G/+)/Gab2(−/−)d o u b l em u t a n tm i c e[ 100].
This further illustrates that interactions between Gab2 and
partners like SHP2 is critical for development of MPD, in
vivo. However, the relative contribution of the Gab2/SHP2
interaction for Erk activation versus the reciprocal inacti-
vation of STAT5 is highly complex and diﬃcult to discern
[21, 90, 91, 100]. Both Erk and STAT5 can drive myelopro-
liferation, and the degree to which they cooperate in normal
and leukemic hematopoiesis is not well deﬁned.
It should be pointed out that although the focus of this
review is on Gabs as interaction partners of oncoproteins
involved in the transformation of hematopoietic cells, the
most thoroughly described roles have been in solid tumors.
Gab2 ampliﬁcation has been seen in nonhematopoietic
cancers such as breast cancer cell lines [79]. Gab2-mediated
activationoftheShp2/Erksignalingpathwayisimportantfor
the proliferation of mammary cells. Ampliﬁcation of Gab2-
containing region has been reported in 10–15% of human
breast tumors [80]. Further supporting this is the in vitro
study whereby overexpression of Gab2 in human MCF-10A
c e l l su s i n gar e t r o v i r a lv e c t o ra p p r o a c h[ 81] gave similar
results. Furthermore, deletion of Gab2 delays migration of
mouse mammary tumors generated using breast cancer cell
lines and this defect can be fully restored by reintroduction
of a plasmid expressing Gab2 [82]. A particular role for
Gab2 and Akt activity has been shown following E2F1
hyperactivation in p27-deﬁcient cells leading to enhanced
cell migration and invasion [101]. A recent study in MCF-
10A epithelial cells show Gab2 overexpression enhances cell
migration and reduces formation of epithelial colonies. Fur-
ther, modulation of focal adhesions by Gab2 was dependent
onShp-2bindingsites.Shp-2bindingdefectmutantrestored
normal cell spreading. In contrast, the Shp-2 aﬃnity mutant
promoted Vav2 phosphorylation and recruitment of some
important RhoA family regulators leading to increased cell
motility [80, 102, 103].
5. Regulation by
PosttranslationalModiﬁcations
The key to ﬁguring out the role of Gabs in hematological
disease is to understand their role in signaling cascades. It is
crucial to visualize these as intertwined loops. Firstly, phos-
phorylation of a particular residue might aﬀectthe phospho-
rylation of a nearby residue in either a positive or antago-
nistic fashion, due to phosphorylation-induced changes in
protein conformation. Secondly, phosphorylation-induced
conformational changes may alter the accessibility of key
regions, such as the PH domain.
Negative feedback regulation of Gab2 can be achieved
by serine phosphorylation at sites near the PH domain
(Akt) or near the SHP-2 binding domain (Erk). Akt can
constitutively associate with Gab2, phosphorylate it on a
consensus phosphorylation site (Ser159) and inhibit Gab2
tyrosine phosphorylation [20]. Mutation of S159A (corre-
sponding mutation in mouse is S160) resulted in increased
tyrosine phosphorylation of Gab2 and the Gab2S159A mutant
displayed transforming properties in ﬁbroblasts and pro-
longed signaling through the PI-3K/Akt pathway. This
might impact downstream STAT5 activity, as it has been
shown that constitutively active STAT5 forms a complex
with the p85 subunit of the PI3-K and Gab2 in leukemic
bone marrow cells, resulting in the activation of Akt [17].
Gab2 is also regulated by Erk-mediated negative feedback
phosphorylation, wherein the identiﬁed S623 is the site of
phosphorylation of Gab2 by Erk. The Gab2/Shp2 interaction
is enhanced by S623A mutation. This is in turn expected
to strongly inhibit downstream STAT5 [19]. Thus, it will
be of relevance to study the balance between positive and
negative signaling through both in vitro models and further
complement it by in vivo analysis. Negative feedback is
deemed critical in shifting Gab2 signaling from Erk and
Akt to STAT5. This mechanism may be particularly relevant
during conditions of hematopoietic stress such as recovery
from myelosuppression or leukemic hematopoiesis. These
conditions are more likely to increase Gab2-mediated Erk
and Akt signaling, while inhibiting STAT5, whereas blockage
or complete deﬁciency of Gab2 might be expected to have a
reverse eﬀect (Figure 3).
6.TargetedTherapy ofGabs?
Since Gabs bind many common receptors and are much less
studied in hematopoiesis, it is pivotal to understand the role
of binding to their partners and how it impacts oncogenic
tyrosine kinase signaling. Due to the fact that all three family
members are potential players in various signaling pathways,
it will be interesting to see the shift in approach for targeting
the Gab family. As discussed earlier, total knockdown of
these proteins has varied physiological and phenotypic
impacts. But, it cannot be emphasized enough that the Gab6 Advances in Hematology
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Figure 3: Potential of stapled peptides in therapeutic intervention. Step 1 illustrates how Erk phosphorylates Gab2 on a consensus
phosphorylation site at serine 623, a residue located between tyrosine 614 and tyrosine 643, which are responsible for Gab2/Src homology
2 domain-containing tyrosine phosphatase- (SHP-) 2 interaction. As is reported in the text, this is part of a negative feedback loop.
Hypothetically a stapled peptide (SP), a biosynthetic molecule binding to a directed region on Gab2, could be introduced in Step 2 to
block the negative regulation by Erk to keep SHP-2 active and STAT5 inactive. Alternatively, it may be necessary to block SHP-2 binding
to Gab2 depending on the disease entity. This ﬁgure elaborates how targeted therapy might provide new direction into understanding the
interactions between adapters, like Gabs, and their partners, and which could ultimately be applied as leukemia therapy.
family members are also key regulators/enhancers of other
oncogenic proteins and could compensate for the deﬁcit of a
family member.
Synthetic peptides that speciﬁcally bind to directed
targets oﬀer an approach for the modulation of receptor
signaling and subsequent gene expression. Stabilized α-helix,
SAH, is a stapled peptide to p53 that has been shown to
prevent p53-MDM4 binding, enabling activation of p53
response and tumor growth suppression both in vitro and
in vivo models [104]. Recently, engineered photoreactive
stapled BH3 peptide helices covalently trap both static and
dynamic protein interactors, and enable rapid identiﬁcation
of interaction sites, providing a new scope for targeted
drug design for the BCL-2 family targets [105]. Visualizing
potential sites on Gabs for similar stapled peptides can
provide fascinating insights into protein-binding disruption.
These disruptions could also uncover the role of binding
partners in disease regulation (Figure 3). In some ways these
directedpeptidescouldbemorepracticalastargetedtherapy,
since they would not silence the entire molecule, like siRNA
targeting, but rather, could disturb binding and interactions
of the target with regulators. However, these interactions
are complex and as mentioned earlier both Erk and STAT5
are important for leukemogenesis, so it remains unclear
whether promoting Gab2/SHP2 interaction to reduce STAT5
activation would be advantageous. The disadvantage of
such a targeted therapy approach would be increased Erk
activation. The therapeutic potential could depend on the
particular upstream activating mutation and the stage of
disease development. The use of new knockin animal models
expressing mutant Gabs would be needed to address these
important issues.
An alternative approach to targeting the speciﬁc eﬀectors
of Gab functional interactions would be to target the entire
molecule as a whole. The risk of this approach is that
it would be predicted to have widespread eﬀects on Erk
and AKT activation, as well as loss of potential negative
regulatory functions. The total Gab targeting approach is
alsocomplicatedbythepotentialredundancyofGab1,Gab2,
and Gab3 for speciﬁc Gab signaling functions. Only through
rational dissection of Gab structure-function as related to
disease progression will targeted therapy for Gabs become
more rationally guided. It is appealing to consider adapter
proteins as drug targets from the respect that they have the
ability to impact upon multiple key oncogenic signals which
may be cooperative. This “killing a ﬂock of birds with one
stone” may be optimal over even “killing two birds with one
stone,” and only adapter proteins permit widespread impact
on receptor-signaling molecule interactions. Therefore, Gabs
are of interest in the ﬁeld of targeted therapeutics and their
complete deletion shows therapeutic potential in mouse
models; however, drug development for these targets will
require moving forward with caution and greater under-
standing of structure-function relationships.
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